{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:28:12Z","timestamp":1791876492821,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":1812,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Frailty &amp; Aging"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.14283\/jfa.2019.25","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T09:43:21Z","timestamp":1614332601000},"page":"215-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review"],"prefix":"10.1016","volume":"8","author":[{"given":"Hira","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.T.","family":"Kouroukis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jfa.2019.25_bib1","series-title":"Lyon, France","author":"Swerdlow","year":"2008"},{"issue":"1","key":"10.14283\/jfa.2019.25_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12465","article-title":"Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis","volume":"163","author":"Pozzi","year":"2013","journal-title":"British journal of haematology"},{"issue":"11","key":"10.14283\/jfa.2019.25_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"17","key":"10.14283\/jfa.2019.25_bib4","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.14283\/jfa.2019.25_bib5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"30","key":"10.14283\/jfa.2019.25_bib6","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.14283\/jfa.2019.25_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.14283\/jfa.2019.25_bib8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"24","key":"10.14283\/jfa.2019.25_bib9","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"10.14283\/jfa.2019.25_bib10","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.1998.16.4.1582","article-title":"Comorbidity and functional status are independent in older cancer patients","volume":"16","author":"Extermann","year":"1998","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.14283\/jfa.2019.25_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.14283\/jfa.2019.25_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/0284186X.2013.840741","article-title":"The effect of a geriatric evaluation on treatment decisions for older cancer patients\u2014a systematic review","volume":"53","author":"Hamaker","year":"2014","journal-title":"Acta Oncol"},{"issue":"13","key":"10.14283\/jfa.2019.25_bib13","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.14283\/jfa.2019.25_bib14","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"American journal of hematology"},{"issue":"5","key":"10.14283\/jfa.2019.25_bib15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.14283\/jfa.2019.25_bib16","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.14283\/jfa.2019.25_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"\u2018Aging ESo, Hematology. Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Current opinion in oncology"},{"issue":"26","key":"10.14283\/jfa.2019.25_bib18","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"5","key":"10.14283\/jfa.2019.25_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2013.03.013","article-title":"Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome","volume":"13","author":"Kleber","year":"2013","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"issue":"9","key":"10.14283\/jfa.2019.25_bib20","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood cancer journal"},{"issue":"1","key":"10.14283\/jfa.2019.25_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clml.2011.09.216","article-title":"Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal","volume":"12","author":"Kleber","year":"2012","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"issue":"4","key":"10.14283\/jfa.2019.25_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5","article-title":"What do we mean by validating a prognostic model?","volume":"19","author":"Altman","year":"2000","journal-title":"Statistics in medicine"},{"issue":"9","key":"10.14283\/jfa.2019.25_bib23","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0895-4356(03)00207-5","article-title":"External validation is necessary in prediction research: a clinical example","volume":"56","author":"Bleeker","year":"2003","journal-title":"Journal of clinical epidemiology"},{"issue":"9","key":"10.14283\/jfa.2019.25_bib24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"10.14283\/jfa.2019.25_bib25","first-page":"1","article-title":"Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials","volume":"23","author":"Gengenbach","year":"2018","journal-title":"Leukemia & lymphoma"},{"key":"10.14283\/jfa.2019.25_bib26","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","author":"Greil","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"10.14283\/jfa.2019.25_bib27","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.3324\/haematol.2018.189969","article-title":"Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I\/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)","volume":"103","author":"Waldschmidt","year":"2018","journal-title":"Haematologica"},{"key":"10.14283\/jfa.2019.25_bib28","series-title":"Clinical Prediction Models","author":"Steyerberg","year":"2008"},{"issue":"12","key":"10.14283\/jfa.2019.25_bib29","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"The Lancet Oncology"},{"key":"10.14283\/jfa.2019.25_bib30","author":"National Comprehensive Cancer Network"},{"issue":"25","key":"10.14283\/jfa.2019.25_bib31","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1200\/JCO.2017.72.8170","article-title":"Time to Stop Saying Geriatric Assessment Is Too Time Consuming","volume":"35","author":"Hamaker","year":"2017","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"10.14283\/jfa.2019.25_bib32","article-title":"Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant","author":"Rosko","year":"2018","journal-title":"Journal of geriatric oncology"},{"issue":"23","key":"10.14283\/jfa.2019.25_bib33","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/blood.V126.23.4239.4239","article-title":"A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial","volume":"126","author":"Facon","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.14283\/jfa.2019.25_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jgo.2017.09.007","article-title":"The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed\/refractory multiple myeloma in the era of novel therapies","volume":"9","author":"Hari","year":"2018","journal-title":"Journal of geriatric oncology"},{"key":"10.14283\/jfa.2019.25_bib35","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.174573","article-title":"From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives","author":"Gay","year":"2018","journal-title":"Haematologica"},{"key":"10.14283\/jfa.2019.25_bib36","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older","author":"Murillo","year":"2018","journal-title":"Journal of geriatric oncology"},{"key":"10.14283\/jfa.2019.25_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1100\/tsw.2001.58","article-title":"Accumulation of deficits as a proxy measure of aging","volume":"1","author":"Mitnitski","year":"2001","journal-title":"ScientificWorldJournal"},{"issue":"7","key":"10.14283\/jfa.2019.25_bib38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2014.110296","article-title":"Age and aging in blood disorders: multiple myeloma","volume":"99","author":"Zweegman","year":"2014","journal-title":"Haematologica"},{"key":"10.14283\/jfa.2019.25_bib39","author":"Alessandra","year":"2018","journal-title":"Efficacy and Feasibility of Dose\/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study"},{"key":"10.14283\/jfa.2019.25_bib40","author":"Claudia","year":"2018","journal-title":"Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study"},{"issue":"1","key":"10.14283\/jfa.2019.25_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41512-017-0008-z","article-title":"Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals","volume":"1","author":"Matino","year":"2017","journal-title":"Diagnostic and Prognostic Research"},{"key":"10.14283\/jfa.2019.25_bib42","doi-asserted-by":"crossref","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"Bmj"}],"container-title":["The Journal of Frailty &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2260134124002949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2260134124002949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T23:24:21Z","timestamp":1736465061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2260134124002949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2260134124002949"],"URL":"https:\/\/doi.org\/10.14283\/jfa.2019.25","relation":{},"ISSN":["2260-1341"],"issn-type":[{"value":"2260-1341","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Frailty & Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jfa.2019.25","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}